Trial Profile

A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 04 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Epcoritamab (Primary) ; Anakinra; Bendamustine; Buclizine; Gemcitabine; Oxaliplatin; Rituximab; Tocilizumab
Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
Focus Registrational; Therapeutic Use
Acronyms EPCORE DLBCL-1; EPCORE&TRADE
Sponsors Genmab

Most Recent Events

16 Jan 2026 Results presented in the AbbVie Media Release.
16 Jan 2026 According to Genmab media release, the full trial results will be submitted for presentation at a future medical meeting.
16 Jan 2026 According to Genmab media release, based on the topline results from the EPCORE DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next steps

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com